US Stock MarketDetailed Quotes
COSM Cosmos Health
- 0.7196
- -0.0404-5.32%
Close Nov 1 16:00 ET
- 0.7334
- +0.0138+1.92%
Post 20:02 ET
15.12MMarket Cap-315P/E (TTM)
0.7866High0.7101Low655.86KVolume0.7699Open0.7600Pre Close491.34KTurnover5.24%Turnover RatioLossP/E (Static)21.01MShares1.650052wk High0.47P/B9.01MFloat Cap0.467752wk Low--Dividend TTM12.52MShs Float194.2500Historical High--Div YieldTTM10.07%Amplitude0.4677Historical Low0.7490Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Cosmos Health Stock Forum
Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%
Positive
Record revenue of $43 million YTD 2024, up 8.62% year-over-year
Gross profit increased by 21%
Projected to exceed $52 million in annualized revenue
Expanded customer base to over 1,500 pharmacies
Negative
None.
All the positive news and then this shit tanked! 😔
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands
Cosmos Health Inc. (NASDAQ:COSM) has reported a significant 160% increase in sales of its proprietary brands on Amazon UK for the year-to-date 2024. Sales have risen to $596,000 from $230,000 during the same period in 2023. The company's CEO, Greg Siokas, expressed satisfaction with the strong reception of their brands in the UK market and anticipates continued growth...
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits
Cosmos Health (NASDAQ:COSM) has entered an exclusive agreement with Virax Biolabs to distribute mpox virus real-time PCR detection kits across India, a market with over 1.4 billion people. This expansion follows a recent second reported case of mpox in India on September 18, 2024. The agreement positions C...
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion
Cosmos Health (NASDAQ:COSM) has entered the development phase for CCDL24, an innovative treatment for gastrointestinal (GI) disorders. The product utilizes advanced biopolymeric grids from natural ingredients to encapsulate bioactive molecules, enhancing drug efficacy at targeted sites. Current efforts...
Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar
Cosmos Health (NASDAQ:COSM) has expanded its exclusive distribution agreement with Virax Biolabs (NASDAQ:VRAX) to commercialize mpox virus real-time PCR detection kits in Gulf Cooperation Council (GCC) countries. This extension builds upon their previous agreement for Greece, Cyprus, and non-exclu...
No comment yet